LeonaBio Advances Lasofoxifene Phase 3 Breast Cancer Trial
BOTHELL, Wash., Aug. 14, 2026 LeonaBio, Inc. reported continued progress in the Phase 3 ELAINE-3 clinical trial evaluating lasofoxifene...
Endocrine Therapy
Advertisement
Annexon Expands Phase 3 ARCHER II Trial in Geographic Atrophy
BRISBANE, Calif., August 12, 202 Annexon, Inc. announced the expansion of its ongoing Phase 3 ARCHER II trial evaluating...
LeonaBio Advances Lasofoxifene in Metastatic Breast Cancer
BOTHELL, Wash., August 12, 2026 LeonaBio, Inc. announced that its lead investigational therapy lasofoxifene will be featured in multiple...
Biocon Secures Health Canada Approval for Yesintek Pen
BENGALURU, Karnataka, India, July 29, 2026 Biocon Limited has announced that its Canadian subsidiary has received Health Canada Notice...
IceCure Seeks NCCN Support for Breast Cancer Cryoablation
CAESAREA, Israel, July 29, 2026 IceCure Medical Ltd. has announced a significant development that could broaden the role of...
Advertisements
Pfizer Expands IBRANCE Label with New FDA Approval for HER2+ Breast Cancer
NEW YORK, June 24, 2026 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved IBRANCE®...
AstraZeneca’s Camizestrant Extends Survival in ESR1-Mutant Breast Cancer
CHICAGO, Illinois, USA, June 2, 2026 AstraZeneca has announced compelling new results from its pivotal Phase III SERENA-6 trial,...
Neurocrine Shows CRENESSITY Sustains CAH Control Data
San Diego, USA – April 22, 2026 In a major advancement for endocrine disorder management, Neurocrine Biosciences has unveiled...
Elacestrant Phase 2 Combo Data Shows Strong PFS in ER+ mBC
FLORENCE, Italy and NEW YORK, December 8, 2025 — The Menarini Group and its oncology subsidiary Stemline Therapeutics unveiled...
FDA Approves Eli Lilly’s Inluriyo for ESR1-Mutated Breast Cancer
Indianapolis, Sept. 25, 2025 – In a landmark advancement for breast cancer treatment, the U.S. Food and Drug Administration...
Advertisement
